Help paying · Medicare negotiated price · pharmacy cost · cycle 2026
Eliquis (apixaban): where help paying exists, what Medicare negotiated and what pharmacies pay
4 assistance programs list apixaban, each with its income ceiling and when we read it. Medicare's negotiated price for a 30-day supply is $231 (in force since January 1, 2026). A scheduled change takes it to $237 on January 1, 2027. Per unit, the negotiated price is 75% of NADAC, the pharmacy acquisition benchmark. 2 non-manufacturing label changes are dated in the last 12 months in the FDA's file. The FDA's enforcement reports name this drug's packages in 1 recall entry. ClinicalTrials.gov lists 61 recruiting trials that name apixaban.
One package, side by side
Price per unit for one package of Eliquis. The negotiated price applies to Medicare Part D; NADAC is a survey of what retail pharmacies pay to buy the drug.
Swipe to read across
Every package we can price
Per-unit prices (per each unit, as the files state). "Scheduled" is a price the CMS file already dates for the future.
| NDC | Product | Unit | Negotiated now | Scheduled | NADAC | Share |
|---|---|---|---|---|---|---|
| 00003-0893-21 | Eliquis | EA | $4.15 | $4.26 | $5.51 | 75% |
| 00003-0893-31 | Eliquis | EA | $4.15 | $4.26 | $5.51 | 75% |
| 00003-0893-41 | (name not listed) | n/a | $4.15 | $4.26 | n/a | no NADAC price |
| 00003-0894-21 | Eliquis | EA | $4.15 | $4.26 | $5.52 | 75% |
| 00003-0894-31 | Eliquis | EA | $4.15 | $4.26 | $5.52 | 75% |
| 00003-0894-41 | (name not listed) | n/a | $4.15 | $4.26 | n/a | no NADAC price |
| 00003-0894-70 | Eliquis | EA | $4.15 | $4.26 | $5.52 | 75% |
| 00003-0898-28 | Eliquis | n/a | $3.85 | $3.95 | n/a | no NADAC price |
| 00003-1028-12 | Eliquis | n/a | $0.481 | $0.494 | n/a | no NADAC price |
| 00003-1028-28 | Eliquis | n/a | $0.481 | $0.494 | n/a | no NADAC price |
| 00003-1028-84 | Eliquis | n/a | $0.481 | $0.494 | n/a | no NADAC price |
| 00003-3764-74 | Eliquis | EA | $4.15 | $4.26 | $5.51 | 75% |
When could a generic arrive
Each date below is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
| Application | Product | Latest listed patent expiry | Latest listed exclusivity expiry | Latest of the two | Set by |
|---|---|---|---|---|---|
| NDA202155 | Eliquis | August 24, 2031 | October 17, 2028 | August 24, 2031 | patent 9326945 with its pediatric extension; 18 dated entries listed |
| NDA220073 | Eliquis | May 22, 2041 | October 17, 2028 | May 22, 2041 | patent 11896586 with its pediatric extension; 6 dated entries listed |
Source: FDA Orange Book data files, edition September 2026, read November 7, 2026; patent listings are as submitted by applicants and not verified by FDA. FDA data file.
Medicare Part D spending
CMS's Medicare Part D spending dataset reports gross spending on Eliquis of $20.77 billion in 2024, across 24,061,332 claims and 4,424,796 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
| Year | Gross spending | Claims | Beneficiaries | Average spending per claim |
|---|---|---|---|---|
| 2024 | $20.77 billion | 24,061,332 | 4,424,796 | $863 |
| 2023 | $18.27 billion | 21,195,452 | 3,927,848 | $862 |
| 2022 | $15.22 billion | 18,973,041 | 3,505,142 | $802 |
| 2021 | $12.58 billion | 17,015,798 | 3,125,087 | $739 |
| 2020 | $9.94 billion | 14,847,081 | 2,641,941 | $669 |
Source: CMS Medicare Part D spending by drug (data-year-2024, modified 2026-06-25), read November 7, 2026. CMS dataset page. All manufacturers combined; the figures are a drug-level aggregate of claims and say nothing about a formulary or coverage.
FDA safety program (REMS)
- Eliquis (application NDA202155): listed as released, without Elements to Assure Safe Use. Program dated December 28, 2012, last modified March 2, 2016. REMS@FDA program page.
A REMS is a safety program the FDA can require for a drug. Some restrict how it is prescribed or dispensed, for example through certified prescribers or pharmacies. This lists what the FDA's REMS@FDA files tie to the application; it does not say which prescribers or pharmacies take part, or whether a given patient needs the program.
Source: FDA REMS@FDA data files (rems-fda-files-2026-11-07-products-20a9945448dd), read November 7, 2026. REMS@FDA product file.
Medicaid use by state
CMS's State Drug Utilization Data records, for 2025, how many prescriptions each state's Medicaid program paid for under this drug's packages and what it reimbursed. The 7 states with the largest reimbursement are shown. Reimbursement is before the rebates manufacturers pay states, so it is not a net cost and not a price a patient pays.
| State | Medicaid-paid prescriptions | Medicaid reimbursed | Covers |
|---|---|---|---|
| NC | 247 | $130,112 | Fee-for-service only |
| PR | 167 | $115,604 | All record types |
| FL | 90 | $53,759 | Fee-for-service only |
| UT | 91 | $48,784 | Fee-for-service only |
| NH | 53 | $37,785 | All record types |
| IA | 66 | $2,780 | All record types |
| MT | 92 | $1,279 | All record types |
Where the publisher suppresses small managed-care cells, a state's figure covers fee-for-service claims only and understates use (4 state and package figures are marked that way here). A state missing from the table means its figures were suppressed or not reported, not zero use. 202 older-year figures are held and left out of the table.
Source: CMS State Drug Utilization Data (State Drug Utilization Data 2025, modified 2026-07-13T15:28:32Z), read November 7, 2026. CMS dataset page. State-reported data compiled by CMS; aggregate by state and package, no provider or patient data.
Where help paying exists
Offers the program pages state
- Manufacturer savings card
The Eliquis savings-and-support page states a Co-pay Card: pay as little as $10 for a 30-day supply or for the first 90-day supply, as little as $30 for subsequent 90-day refills for up to 24 months, with a maximum annual benefit of $2,000. Activation and first use must take place by December 31, 2026, and the card expires 24 months from activation.
Limited time: Activation and first use must take place by December 31, 2026.
Read November 7, 2026; quote matched against the saved page text. - Manufacturer self-pay price
The Eliquis savings-and-support page states that a patient without insurance may be eligible to purchase ELIQUIS directly through ELIQUIS 360 Support. The page gives no price; it links to pricing information that was not read.
Read November 7, 2026; quote matched against the saved page text. - Manufacturer offer
The Eliquis savings-and-support page states a Free 30-Day Trial offer: a free 30-day supply (up to 74 tablets) of ELIQUIS for eligible first-time patients with a valid 30-day prescription, one use per patient per lifetime, not billable to insurance or government programs, with the card expiring on December 31, 2026.
Limited time: The card expires on December 31, 2026.
Read November 7, 2026; quote matched against the saved page text.
Programs in our finder that list apixaban. Each shows its income ceiling, when we read it and whether we checked it against the program's own document. Eligibility is decided by the program, not by us.
- Pfizer RxPathways manufacturer
Income at or below 300% FPL ($47,880 for one person in 2026)
Ceiling matched against the program's page text, November 6, 2026.Status. Pfizer RxPathways lists the products that remain in its Patient Assistance Program as of January 1, 2026, and marks Xeljanz and Bosulif as taking no new patients starting July 1, 2026. The page also notes the product list is subject to change. (read November 7, 2026)
- Bristol Myers Squibb Patient Assistance Foundation manufacturer
Income at or below $47,880 for one person for Eliquis (BMS Patient Assistance Foundation, read 13 October 2026)
Limit read October 13, 2026. - BMS Eliquis 360 Support Savings Card manufacturer
No income limit in our data
Figure not yet re-read on the program's own page. - HealthWell Foundation nonprofit
Up to 300% to 500% FPL depending on the disease fund; many funds close to new patients
Ceiling matched against the program's page text, November 6, 2026.Status. The HealthWell Foundation homepage lists disease funds as Open or Closed when read. Closed funds include Type 2 Diabetes, Migraine and Multiple Sclerosis - Medicare Access; open funds include Multiple Myeloma - Medicare Access, which the page says offers up to $8,000 in prescription drug copayment or Medicare Part B premium assistance. The page carries no fund-level date; the status is as of the read. (read November 7, 2026)
Check where your income sits against each ceiling: open the assistance finder. See what has changed and when we last verified each program on the program status board.
Label changes
FDA actions on the applications behind Eliquis dated since November 11, 2025, leaving out manufacturing (CMC) changes. 2 changes in the window.
| Date | Class | Application | Submissions | FDA documents |
|---|---|---|---|---|
| June 24, 2026 | Labeling | NDA202155 | 42 | Label (PDF) posted June 29, 2026FDA letter posted June 26, 2026 |
| June 24, 2026 | Labeling | NDA220073 | 1 | Label (PDF) posted June 29, 2026FDA letter posted June 26, 2026 |
Source: FDA Drugs@FDA data file, read November 7, 2026. Dates are the FDA action dates; the documents are on FDA's own site. FDA data file. All recent changes across these drugs: label changes feed.
Safety notices
FDA enforcement report entries that name a package of Eliquis by its NDC: 1 entry, newest first. FDA assigns each a class by health risk: Class I is the most serious and Class III the least. An entry records what the recalling firm reported and FDA classified; it is not advice about any package you hold.
| Reported | Class | Status | Recalling firm | Reason (shortened) | Packages named |
|---|---|---|---|---|---|
| July 19, 2017D-0959-2017 | Class I | Terminated | Bristol-myers Squibb Company | Labeling: Label Mix-up: One bottle of Eliquis 5 mg tablet was found to contain lower-strength Eliquis 2.5 mg tablets only instead of the labeled 5 mg tablets. | 1 |
Source: openFDA drug enforcement reports, file read November 7, 2026. openFDA data file. All recent recalls across these drugs: drug recalls feed.
Clinical trials recruiting
ClinicalTrials.gov lists 61 interventional trials that name apixaban and are recruiting, and 25 more not yet recruiting. By phase: Phase 4: 21, Phase 3: 18, Not applicable: 14, Phase 2: 4, Phase 1: 2, Early phase 1: 2. The 10 most recently updated are below. A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
| Trial | Title and conditions | Phase | Lead sponsor | Last updated | Countries |
|---|---|---|---|---|---|
| NCT07015905 | REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in AdultsVenous Thromboembolism (VTE) | Phase 3 | Regeneron Pharmaceuticals | November 6, 2026 | United States, Bulgaria, Hungary and 5 more |
| NCT07175428 | Safety in Adult Participants With Atrial Fibrillation Who Are Treated With AnticoagulationAtrial Fibrillation (AF) | Phase 2 | Regeneron Pharmaceuticals | November 5, 2026 | United States, Argentina, Brazil and 1 more |
| NCT07493304 | Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic CancersVenous Thromboembolism (VTE) | Phase 3 | Regeneron Pharmaceuticals | November 5, 2026 | United States, Bulgaria, Japan and 2 more |
| NCT07626411 | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial FibrillationAtrial Fibrillation (AF) | Phase 3 | Regeneron Pharmaceuticals | November 5, 2026 | United States, Canada, Japan |
| NCT07471139 | SWITCH: Apixaban vs Vitamin K in HM3LVAD (Left Ventricular Assist Device) Thrombosis; Heart Failure; Bleeding | Phase 3 | Columbia University | November 4, 2026 | United States |
| NCT05701917 | DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein ThrombosisVenous Thromboembolism; Deep Venous Thrombosis; Post-Thrombotic Syndrome | Not applicable | Inari Medical | November 3, 2026 | United States, Austria, Finland and 3 more |
| NCT06401616 | Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)Atrial Fibrillation; Left Atrial Appendage Absent; Anticoagulant Adverse Reaction | Phase 4 | Odense University Hospital | October 21, 2026 | Denmark |
| NCT07869615 | Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee ArthroplastyTotal Knee Arthroplasty; Venous Thromboembolism | Not applicable | Military Hospital of Tunis | October 16, 2026 | Tunisia |
| NCT07237308 | BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral AtherosclerosisStroke; Ischemic; Atrial Fibrillation | Phase 4 | Yonsei University | October 16, 2026 | South Korea |
| NCT07840365 | Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage OcclusionAtrial Fibrillation (AF) | Phase 3 | Texas Cardiac Arrhythmia Research Foundation | October 5, 2026 | United States |
Source: ClinicalTrials.gov, registry data processed November 6, 2026, summarized and trimmed by OmniRx. Search on ClinicalTrials.gov.
Questions
What is the Medicare negotiated price of Eliquis?
For a 30-day supply the price CMS published is $231, in force since January 1, 2026. The CMS file also schedules $237 from January 1, 2027. This is a price CMS agreed with the manufacturer for Medicare Part D, not what a person pays at the counter.
How does the negotiated price compare with what pharmacies pay?
Across the 6 packages where both CMS files give a price per unit, the median negotiated price is 75% of NADAC, the pharmacy acquisition benchmark (NADAC as of November 4, 2026). NADAC is a survey average, not a quote.
Is there help paying for Eliquis?
4 assistance programs list it in our finder. Eligibility depends on income, coverage and the program's current rules; each program's own page decides.
When could a generic version of Eliquis arrive?
For Eliquis, the FDA's Orange Book (edition September 2026) lists these latest patent or exclusivity expiry dates by application: NDA202155, August 24, 2031; NDA220073, May 22, 2041. Each date is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
Can I join a clinical trial for Eliquis?
ClinicalTrials.gov lists 61 recruiting interventional trials that name apixaban (registry data processed November 6, 2026). A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
How much does Medicare Part D spend on Eliquis?
CMS's Medicare Part D spending dataset reports gross spending on Eliquis of $20.77 billion in 2024, across 24,061,332 claims and 4,424,796 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
For developers: this drug as data
One call returns price, generic-entry upper bound, label history, recalls, trials, assistance, and where facts exist the FDA safety program (REMS), DEA schedule, orphan designations, safety notices and Medicaid use by state, each with receipts.
Example file: https://omnirx.org/api/v1/dossier/eliquis.json
The licence page sets out what a data licence covers, and the API page documents these files.
Evaluation files with receipts; contract may change; not clinical advice.
Sources and terms. CMS Medicare Drug Price Negotiation Program data file (read November 6, 2026; the CMS page states no licence or restriction); CMS NADAC from data.medicaid.gov under the labels in the OmniRx licence ledger; program details read from each program's own pages; CMS Medicare Part D spending by drug; FDA Drugs@FDA and Orange Book data files; openFDA drug enforcement reports; ClinicalTrials.gov registry data. Figures are stored with their sources in the OmniRx library (edition 2026-11). Free to cite with attribution. Not medical, legal or financial advice. Report an error through the contact page. Licence the data.